

21 February 2019

To: Recipients of M100, 29th ed.  
From: Jennifer K. Adams, MT(ASCP), MSHA  
Vice President, Standards and Quality  
Subject: Correction

This notification is to inform you of corrections made to CLSI document M100, *Performance Standards for Antimicrobial Susceptibility Testing*, 29th ed. The corrections are described below and shown as highlighted and/or stricken text in the table excerpts.

**Table 4A-2. Disk Diffusion QC Ranges for Nonfastidious Organisms and B-Lactam Combination Agents:**

In the ceftolozane-tazobactam row, the green shading indicating the recommended quality control (QC) strain was omitted from the QC range cell for *Klebsiella pneumoniae* ATCC® 700603. The table has been corrected to include the shading in the QC range cell for ceftolozane-tazobactam and *K. pneumoniae* ATCC® 700603.

**Table 4A-2. Disk Diffusion QC Ranges for Nonfastidious Organisms and B-Lactam Combination Agents**

Antimicrobial Agent	Disk Content	QC Organisms and Characteristics				
		<i>Escherichia coli</i> ATCC® <sup>a</sup> 25922	<i>Pseudomonas aeruginosa</i> ATCC® 27853	<i>Staphylococcus aureus</i> ATCC® 25923	<i>Escherichia coli</i> ATCC® <sup>b,c</sup> 35218	<i>Klebsiella pneumoniae</i> ATCC® 700603 <sup>b,c</sup>
		B-lactamase negative	Inducible AmpC	B-lactamase negative, <i>mecA</i> negative	TEM-1	SHV-18 OXA-2 Mutations in OmpK35 and OmpK37 TEM-1
Zone Diameter QC Ranges, mm						
Ceftolozane-tazobactam	30/10 µg	24-32	25-31	10-18	25-31	17-25

**QC strain selection codes:** QC strain is recommended for routine QC.  
Test one of these agents by a disk diffusion or MIC method to confirm the integrity of the respective QC strain.<sup>b,c</sup>

**Appendix E. Dosage Regimens Used to Establish Susceptible or Susceptible-Dose Dependent Breakpoints:**

The dosage regimen used to establish the susceptible breakpoint for levofloxacin for *Pseudomonas aeruginosa* is listed incorrectly as "750 mg administered every 8 h." The dosage regimen has been corrected to read "750 mg administered every 24 h" for consistency with the dosage regimen listed in Table 2B-1.

**Appendix E. Dosage Regimens Used to Establish Susceptible or Susceptible-Dose Dependent Breakpoints**

Antimicrobial Agent	Breakpoints and Interpretive Categories			
	Susceptible		SDD	
	MIC	Dose	MIC	Dose
<i>Table 2B-1. Pseudomonas aeruginosa</i>				
Levofloxacin	≤ 1 µg/mL	750 mg administered every 8-24 h	N/A	

If you require any additional clarification regarding these corrections, please contact CLSI Customer Service ([customerservice@clsi.org](mailto:customerservice@clsi.org)).

We appreciate your commitment to CLSI and regret any inconvenience.